(Q40718402)

English

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

scientific article published on 23 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents (English)

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

Julio Rosenstock

8

object named as

Julio Rosenstock

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Eduard Montanya

object named as

Eduard Montanya

4

0 references

object named as

Giorgio Sesti

2

0 references

object named as

John B Buse

1

0 references

author name string

Wolfgang E Schmidt

3

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Cheng-Tao Chang

5

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Yizhen Xu

6

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Lawrence Blonde

7

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Liraglutide Effect Action in Diabetes-6 Study Group

9

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

language of work or name

0 references

publication date

23 March 2010

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

33

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

6

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

1300-1303

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

28 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

25 September 2017

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

25 September 2017

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

25 September 2017

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

25 September 2017

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

25 September 2017

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

25 September 2017

Can newer therapies delay the progression of type 2 diabetes mellitus?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

25 September 2017

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

19 August 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

19 August 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

19 August 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875443

19 August 2018

Identifiers

10.2337/DC09-2260

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40718402&oldid=1905129220"